HIV and AIDS Trial, Recruiting NCT00187512 Sponsor: University of California, San Francisco Condition: HIV and AIDS
Back to Hiv Aids

HIV and AIDS Trial, Recruiting

NCT00187512
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are HIV-1 positive and your HIV viral load (the amount of virus in your blood) is below 2,000 copies/ml without taking any HIV medications.
  • You are HIV-1 positive, taking a stable HIV medication regimen, your virus is undetectable in your blood, but your immune cells (CD4 T-cells) have stayed below 350 for the past 12 months.
  • You are HIV-1 positive, have never taken HIV medications before, and are planning to start taking them — any blood test results are acceptable for this group.
  • You have been HIV-positive for at least 10 years, have not taken any HIV medications for 10 or more years, and your immune cell count (CD4 T-cells) has always stayed above 500 — any viral load is acceptable for this group.

Who may not be able to join:

  • You currently have an active serious infection related to a weakened immune system, or you have been treated for one in the last 4 months (a mouth yeast infection is generally still acceptable).
  • You are currently receiving treatment for cancer.
  • You are currently being treated for hepatitis C with a treatment that includes interferon.
  • You have taken medications that suppress the immune system within the last 4 months.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Steven G. Deeks, M.D., University of California, San Francisco

Phone: 415-476-4082

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 March 2000
Est. completion
1 December 2032

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

The general theme of this core is to investigate the relationship between the virologic response to antiretroviral therapy and clinical outcome.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov